Cargando…
IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients
BACKGROUND: The 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) is a current worldwide threat for which the immunological features after infection need to be investigated. The aim of this study was to establish a highly sensitive...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683808/ https://www.ncbi.nlm.nih.gov/pubmed/34922455 http://dx.doi.org/10.1186/s12866-021-02401-0 |
_version_ | 1784617497029246976 |
---|---|
author | Yang, Li Xu, Qiang Yang, Bin Li, Jiayu Dong, Rong Da, Jingjing Ye, Zhixu Xu, Yongjie Zhou, Hourong Zhang, Xiangyan Liu, Lin Zha, Yan Yu, Fuxun |
author_facet | Yang, Li Xu, Qiang Yang, Bin Li, Jiayu Dong, Rong Da, Jingjing Ye, Zhixu Xu, Yongjie Zhou, Hourong Zhang, Xiangyan Liu, Lin Zha, Yan Yu, Fuxun |
author_sort | Yang, Li |
collection | PubMed |
description | BACKGROUND: The 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) is a current worldwide threat for which the immunological features after infection need to be investigated. The aim of this study was to establish a highly sensitive and quantitative detection method for SARS-CoV-2 IgG antibody and to compare the antibody reaction difference in patients with different disease severity. RESULTS: Recombinant SARS-CoV-2 nucleocapsid protein was expressed in Escherichia coli and purified to establish an indirect IgG ELISA detection system. The sensitivity of the ELISA was 100% with a specificity of 96.8% and a 98.3% concordance when compared to a colloidal gold kit, in addition, the sensitivity of the ELISA was 100% with a specificity of 98.9% and a 99.4% concordance when compared to a SARS-CoV-2 spike S1 protein IgG antibody ELISA kit. The increased sensitivity resulted in a higher rate of IgG antibody detection for COVID-19 patients. Moreover, the quantitative detection can be conducted with a much higher serum dilution (1:400 vs 1:10, 1:400 vs 1:100). The antibody titers of 88 patients with differing COVID-19 severity at their early convalescence ranged from 800 to 102,400, and the geometric mean titer for severe and critical cases, moderate cases, asymptomatic and mild cases was 51,203, 20,912, and 9590 respectively. CONCLUSION: The development of a highly sensitive ELISA system for the detection of SARS-CoV-2 IgG antibodies is described herein. This system enabled a quantitative study of rSARS-CoV-2-N IgG antibody titers in COVID-19 patients, the occurrence of higher IgG antibody titers were found to be correlated with more severe cases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12866-021-02401-0. |
format | Online Article Text |
id | pubmed-8683808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86838082021-12-20 IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients Yang, Li Xu, Qiang Yang, Bin Li, Jiayu Dong, Rong Da, Jingjing Ye, Zhixu Xu, Yongjie Zhou, Hourong Zhang, Xiangyan Liu, Lin Zha, Yan Yu, Fuxun BMC Microbiol Research BACKGROUND: The 2019 novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) is a current worldwide threat for which the immunological features after infection need to be investigated. The aim of this study was to establish a highly sensitive and quantitative detection method for SARS-CoV-2 IgG antibody and to compare the antibody reaction difference in patients with different disease severity. RESULTS: Recombinant SARS-CoV-2 nucleocapsid protein was expressed in Escherichia coli and purified to establish an indirect IgG ELISA detection system. The sensitivity of the ELISA was 100% with a specificity of 96.8% and a 98.3% concordance when compared to a colloidal gold kit, in addition, the sensitivity of the ELISA was 100% with a specificity of 98.9% and a 99.4% concordance when compared to a SARS-CoV-2 spike S1 protein IgG antibody ELISA kit. The increased sensitivity resulted in a higher rate of IgG antibody detection for COVID-19 patients. Moreover, the quantitative detection can be conducted with a much higher serum dilution (1:400 vs 1:10, 1:400 vs 1:100). The antibody titers of 88 patients with differing COVID-19 severity at their early convalescence ranged from 800 to 102,400, and the geometric mean titer for severe and critical cases, moderate cases, asymptomatic and mild cases was 51,203, 20,912, and 9590 respectively. CONCLUSION: The development of a highly sensitive ELISA system for the detection of SARS-CoV-2 IgG antibodies is described herein. This system enabled a quantitative study of rSARS-CoV-2-N IgG antibody titers in COVID-19 patients, the occurrence of higher IgG antibody titers were found to be correlated with more severe cases. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12866-021-02401-0. BioMed Central 2021-12-18 /pmc/articles/PMC8683808/ /pubmed/34922455 http://dx.doi.org/10.1186/s12866-021-02401-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yang, Li Xu, Qiang Yang, Bin Li, Jiayu Dong, Rong Da, Jingjing Ye, Zhixu Xu, Yongjie Zhou, Hourong Zhang, Xiangyan Liu, Lin Zha, Yan Yu, Fuxun IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients |
title | IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients |
title_full | IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients |
title_fullStr | IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients |
title_full_unstemmed | IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients |
title_short | IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients |
title_sort | igg antibody titers against sars-cov-2 nucleocapsid protein correlate with the severity of covid-19 patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683808/ https://www.ncbi.nlm.nih.gov/pubmed/34922455 http://dx.doi.org/10.1186/s12866-021-02401-0 |
work_keys_str_mv | AT yangli iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT xuqiang iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT yangbin iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT lijiayu iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT dongrong iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT dajingjing iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT yezhixu iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT xuyongjie iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT zhouhourong iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT zhangxiangyan iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT liulin iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT zhayan iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients AT yufuxun iggantibodytitersagainstsarscov2nucleocapsidproteincorrelatewiththeseverityofcovid19patients |